The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30
- PMID: 19714488
- DOI: 10.1007/s10689-009-9287-z
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30
Abstract
Germ-line mutations in the TP53 gene are rare, but predispose women to a range of cancer types, including early-onset breast cancer. Breast cancers in women from families with the Li-Fraumeni syndrome often occur before age 30. The prevalence of deleterious TP53 mutations in unselected women with early-onset breast cancer is not precisely known. If mutations were found to be sufficiently common, it might be prudent to offer genetic testing to affected women in this age group. We screened the entire TP53 gene in the germ-line DNA from 95 women of various ethnic groups who were diagnosed with breast cancer before age 30, and who had previously been found to be negative for BRCA1 and BRCA2 mutations. No TP53 mutation was found. This study does not support a policy that TP53 testing should be offered routinely to unselected women with early-onset breast cancer in the absence of a family history of cancer.
Similar articles
-
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.Breast Cancer Res Treat. 2008 Apr;108(3):399-408. doi: 10.1007/s10549-007-9608-6. Epub 2007 May 31. Breast Cancer Res Treat. 2008. PMID: 17541742
-
The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.Fam Cancer. 2021 Jul;20(3):173-180. doi: 10.1007/s10689-020-00212-2. Epub 2020 Oct 14. Fam Cancer. 2021. PMID: 33051812
-
Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.BMC Cancer. 2019 Feb 1;19(1):118. doi: 10.1186/s12885-019-5312-2. BMC Cancer. 2019. PMID: 30709381 Free PMC article.
-
Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.Hum Mutat. 2018 Dec;39(12):1764-1773. doi: 10.1002/humu.23656. Epub 2018 Oct 3. Hum Mutat. 2018. PMID: 30240537 Review.
-
The Li-Fraumeni syndrome: an inherited susceptibility to cancer.Mol Med Today. 1997 Sep;3(9):390-5. doi: 10.1016/S1357-4310(97)01105-2. Mol Med Today. 1997. PMID: 9302689 Review.
Cited by
-
Breast cancer in young women.Breast Cancer Res. 2010;12(5):212. doi: 10.1186/bcr2647. Epub 2010 Oct 28. Breast Cancer Res. 2010. PMID: 21067532 Free PMC article. Review.
-
The tip of the iceberg: a countercurrents series.Curr Oncol. 2012 Jun;19(3):129-30. doi: 10.3747/co.19.1103. Curr Oncol. 2012. PMID: 22670089 Free PMC article. No abstract available.
-
Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.Int J Clin Oncol. 2021 Dec;26(12):2161-2178. doi: 10.1007/s10147-021-02011-w. Epub 2021 Oct 11. Int J Clin Oncol. 2021. PMID: 34633580 Free PMC article.
-
Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.PLoS One. 2013;8(3):e57581. doi: 10.1371/journal.pone.0057581. Epub 2013 Mar 1. PLoS One. 2013. PMID: 23469205 Free PMC article.
-
Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.Fam Cancer. 2012 Jun;11(2):307-11. doi: 10.1007/s10689-012-9509-7. Fam Cancer. 2012. PMID: 22311583
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous